Phreesia, Inc. (PHR)
| Market Cap | 630.02M -55.8% |
| Revenue (ttm) | 507.79M +12.9% |
| Net Income | 10.45M |
| EPS | 0.17 |
| Shares Out | 62.07M |
| PE Ratio | 59.09 |
| Forward PE | 17.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 757,838 |
| Open | 9.97 |
| Previous Close | 10.00 |
| Day's Range | 9.97 - 10.25 |
| 52-Week Range | 7.77 - 24.25 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 13.94 (+37.34%) |
| Earnings Date | Sep 2, 2026 |
About PHR
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for PHR stock is "Buy." The 12-month stock price target is $13.94, which is an increase of 37.34% from the latest price.
News
Phreesia's ProviderConnect Audiences are Now Available in the DeepIntent Audience Marketplace
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia's ProviderConnect audiences are now available in the DeepIntent Audience Marketplace.
Phreesia downgraded to Market Perform from Outperform at Raymond James
Raymond James downgraded Phreesia (PHR) to Market Perform from Outperform without a price target The Q2 results were modestly ahead, but weakening organic growth, increased AI investment, pressure on ...
Phreesia price target lowered to $13 from $14 at DA Davidson
DA Davidson lowered the firm’s price target on Phreesia (PHR) to $13 from $14 and keeps a Buy rating on the shares. The stock fell as the management reiterated its…
Phreesia price target raised to $11 from $10 at Baird
Baird analyst Joe Vruwink raised the firm’s price target on Phreesia (PHR) to $11 from $10 and keeps a Neutral rating on the shares. The firm updated its model following…
Phreesia files automatic mixed securities shelf
16:56 EDT Phreesia (PHR) files automatic mixed securities shelf
Phreesia price target raised to $10 from $9 at Wells Fargo
Wells Fargo raised the firm’s price target on Phreesia (PHR) to $10 from $9 and keeps an Equal Weight rating on the shares. The firm notes Q2 was largely as…
Phreesia Earnings Call Transcript: Q2 2027
Q2 FY2027 saw 10% revenue growth year-over-year, strong profitability, and positive cash flow, enabling a $23M debt reduction. Product innovation and segment expansion, especially AccessOne and ProviderConnect, are driving growth, with FY2027 guidance reaffirmed.
Phreesia Earnings release: Q2 2027
Phreesia released its Q2 2027 earnings on September 2, 2026, summarizing the period's financial results.
Phreesia Slides: Q2 2027
Phreesia has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on September 2, 2026.
Phreesia Shareholder letter: Q2 2027
Phreesia has published a letter to shareholders covering Q2 2027, which was released on September 2, 2026.
Phreesia Quarterly report: Q2 2027
Phreesia has published its Q2 2027 quarterly earnings report on September 2, 2026.
Phreesia reports Q2 EPS 3c vs. 1c last year
Reports Q2 revenue $129.5M, consensus $129.0M. Average number of healthcare services clients (“AHSCs”) was 4,744 in the quarter, up 6% year-over-year. Total revenue per AHSC was $27,289 in the quarter...
Phreesia Announces Second Quarter Fiscal 2027 Results
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2026. “Phr...
Phreesia Sets Release Date for Fiscal Second Quarter 2027 Results
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia will release its fiscal second quarter 2027 financial results after the close of market trading on Wednesday, Sept. 2, 2026.
Phreesia and March of Dimes Partner to Help Strengthen Physician-Patient Conversations and Improve the Health of Moms and Babies
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia and March of Dimes announce a partnership to enhance critical physician-patient conversations during prenatal and postpartum appointments...
MediFind Launches AI-Powered Chatbot to Help Patients Find and Book the Right Provider
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--MediFind, a data-powered online provider directory offered by Phreesia, is announcing the launch of Chloe, its new “Find the Right Provider” chatb...
Robbins LLP is Investigating Allegations that Phreesia, Inc. (PHR) Misled Investors Regarding the Sustainability of Growth in its Network Solutions Business and Fiscal 2027 Revenue Outlook
San Diego, California--(Newsfile Corp. - July 6, 2026) - Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Phreesia, Inc. (N...
Phreesia Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by stockholders. No questions were submitted, and a quorum was established. Final voting results will be filed with the SEC.
PHR Stockholders Have Rights – If You Lost Money Investing in Phreesia, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO--(BUSINESS WIRE)---- $PHR #Inc--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Phreesia, Inc. (NYSE: PHR) commo...
Phreesia downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler downgraded Phreesia (PHR) to Neutral from Overweight with a price target of $12, down from $23.
Phreesia downgraded to Neutral at Piper on lack of growth visibility
Piper Sandler analyst Jessica Tassan downgraded Phreesia (PHR) to Neutral from Overweight with a price target of $12, down from $23. Phreesia is cutting costs to find profitability, but without…
Phreesia price target lowered to $16 from $22 at Canaccord
Canaccord lowered the firm’s price target on Phreesia (PHR) to $16 from $22 and keeps a Buy rating on the shares. The firm said Phreesia beat consensus revenue and adj-EBITDA…
Phreesia price target raised to $12 from $10 at Citi
Citi raised the firm’s price target on Phreesia (PHR) to $12 from $10 and keeps a Neutral rating on the shares. The company’s fiscal Q1 report came in better than…
Phreesia affirms FY27 revenue view of $510M-$520M, consensus $515.7M
The company states: “We are maintaining our revenue outlook for fiscal 2027. We expect revenue to be in the range of $510 million to $520 million. As we noted last…
Phreesia up 12% at $10.21 after Q1 results, affirmed guidance
16:28 EDT Phreesia (PHR) up 12% at $10.21 after Q1 results, affirmed guidance